ALI HEALTH

Alibaba Health rose about 2.6% to HK$3.59 today, driven primarily by the announcement of a board restructuring aimed at bolstering governance, which included the resignation of non-executive director Xu Haipeng effective July 29, 2026. In morning trading, the stock touched a high of HK$3.63, retreating to HK$3.59 by the close, on turnover of over 100 million shares and HK$356 million in value. Latest Q4 results showed operating revenue of HK$9.953 billion, up 13.86% year-over-year, and net profit of HK$380 million, up 6.83% year-over-year. From a valuation perspective, the stock has rebounded roughly 18% from its 52-week low of HK$3.04 set in late June, though it remains down 31.09% year-to-date and off 54.61% from the 52-week high of HK$7.91 in January; the current price sits slightly above the 20-day moving average of HK$3.423. That said, UBS has recently cut its price target citing headwinds from China's pharmaceutical retail regulations, leaving near-term sentiment contingent on whether the management reshuffle can address structural industry pressures.

The stock closed at HK$3.530, down 1.7%, after declining from HK$3.650 at 9:30 morning session open to HK$3.550 by late morning, then opening afternoon at HK$3.540 and further weakening to a low of HK$3.500 before settling at HK$3.530, reflecting profit-taking pressure. Recent board restructuring initiatives to strengthen governance and non-executive director changes drew market attention. On the earnings front, Q4 operating revenue reached HK$99.5 billion, up 13.86% year-over-year, with net profit up 6.83%, demonstrating resilient growth. Price-wise, the stock has declined 32.25% year-to-date and now trades near June's 52-week lows, having retreated over 55% from the HK$7.91 peak. While fundamentals show respectable growth, concerns over pharmaceutical retail regulation and elevated short interest continue to pressure the stock.

AliHealth closed at HK$3.43, flat against the prior session, reflecting divergent market sentiment regarding the company's medium-term prospects. Year-to-date performance has deteriorated 34.17%, erasing over 56% from the January peak of HK$7.91, currently trading near the 52-week low of HK$3.04 established in late June, underscoring persistent bearish pressure from short sellers. Recent institutional developments indicate that UBS and other major investors have trimmed target prices, signaling a more defensive investment posture. From an operational standpoint, the company's fundamentals continue to improve: FY2026 revenues grew 13.86% to HK$9.95 billion, net profit increased 6.83% to HK$380 million, and earnings per share expanded 6.57% year-over-year. With a current PE valuation of 25.3x, the stock appears reasonably valued relative to earnings growth. While the stock faces renewed short-term headwinds from increased short-selling activity, the company's underlying operational performance remains relatively solid.

Alibaba Health advanced 2.1% to HK$3.41 today, supported by its FY2026 annual results and a technical rebound following recent sharp declines. The company reported operating revenue of HK$9.953 billion, up 13.86% year-over-year, and net profit of HK$379.5 million, up 6.83%, demonstrating resilience despite sequential deceleration. Morning trading saw strength with the stock rising to HK$3.43, though afternoon profit-taking pressure led to a mild pullback at the close. A significant headwind remains the recent downward revision of price targets by UBS and other analysts citing uncertainty around China's pharmaceutical retail regulations. From a valuation standpoint, the stock has approached its 52-week low of HK$3.04 (only about 12% buffer), with a year-to-date decline of 34.55%. Currently trading marginally above its 20-day moving average of HK$3.351 but notably below the 60-day average of HK$3.678, the stock continues to consolidate at depressed levels.

Alibaba Health slid 2.6% to HKD3.34, primarily pressured by UBS's recent downward target price adjustment on the sector. Trading showed volatility, retreating from HKD3.38 at opening to HKD3.31 in late morning before recovering to HKD3.34 at close, with 80.5 million shares traded for HKD268 million in turnover. Fundamentals remained solid—Q4 operating revenue reached HKD9.95 billion (+13.86% YoY), net profit HKD379 million (+6.83% YoY), and EPS up 6.57% year-over-year. Yet the stock faces clear headwinds, trading 57.77% below its 52-week peak of HKD7.91 and sitting just 9.87% above the June low of HKD3.04, hovering near the 20-day MA of HKD3.334. Elevated short interest adds pressure. Meanwhile, Bank of America had set a HKD5.1 target price with a Buy rating in early January, while UBS's recent move signals growing institutional divergence; combined with a PE of 24.6x and thin 0.5% turnover, market participation remains subdued.